Citation: | LIAO Wen-sheng, SHAO Yan-xiang, SUN Guang-xi, et al. Application of Prognostic Predication Model in Clinical Non-metastatic Renal Cell Carcinoma[J]. Journal of Sichuan University (Medical Sciences), 2019, 50(5): 720-724. |
[1] |
ALAN J W, LOUIS R K, AKAN W P, CRAIG A P. Campbell-Walsh.Urology, 11th, 2016. ELSEVIER, USA, 2016. https://www.abe.pl/en/default/error/error
|
[2] |
CHOW W H, DEVESA S S.Contemporary epidemiology of renal cell cancer. Cancer J, 2008, 14(5):288-301. DOI: 10.1097/PPO.0b013e3181867628
|
[3] |
ZISMAN A, PANTUCK A J, DOREY F, et al. Mathematical model to predict individual survival for patients with renal cell carcinoma. J Clin Oncol, 2002, 20:1368-1374. DOI: 10.1200/JCO.2002.20.5.1368
|
[4] |
ZISMAN A, PANTUCK A J, DOREY F, et al. Improved prognostication of renal cell carcinoma using an integrated staging system. J Clin Oncol, 2001, 19(6):1649-1657. DOI: 10.1200/JCO.2001.19.6.1649
|
[5] |
LEIBOVICH B C, BLUTE M L, CHEVILLE J C, et al. Prediction of progression after radical nephrectomy for patients with clear cell renal cell carcinoma:a stratification tool for prospective clinical trials. Cancer, 2003, 97(7):1663-1671. DOI: 10.1002/cncr.11234
|
[6] |
FRANK I, BLUTE M L, CHEVILLE J C, et al. An outcome prediction model for patients with clear cell renal cell carcinoma treated with radical nephrectomy based on tumor stage, size, grade and necrosis:the SSIGN score. J Urol, 2002, 168(6):2395-2400. DOI: 10.1016/S0022-5347(05)64153-5
|
[7] |
ROY-CHAUDHURY P, ARNOLD P, SEIGEL J, et al. From basic biology to randomized clinical trial:the Beta Radiation for Arteriovenous Graft Outflow Stenosis (BRAVO Ⅱ). Semin Dial, 2013, 26(2):227-232. DOI: 10.1111/sdi.12000
|
[8] |
KARAKIEWICZ P I, BRIGANTI A, CHUN F K, et al. Multi-institutional validation of a new renal cancer-specific survival nomogram. J Clin Oncol, 2007, 25(11):1316-1322. DOI: 10.1200/JCO.2006.06.1218
|
[9] |
ZIGEUNER R, HUTTERER G, CHROMECKI T, et al. External validation of the Mayo Clinic stage, size, grade, and necrosis (SSIGN) score for clear-cell renal cell carcinoma in a single European centre applying routine pathology. Eur Urol, 2010, 57(1):102-109. DOI: 10.1016/j.eururo.2008.11.033
|
[10] |
CINDOLO L, CHIODINI P, GALLO C, et al. Validation by calibration of the UCLA integrated staging system prognostic model for nonmetastatic renal cell carcinoma after nephrectomy. Cancer, 2008, 113(1):65-71. DOI: 10.1002/cncr.23517
|
[11] |
CINDOLO L, PATARD J J, CHIODINI P, et al. Comparison of predictive accuracy of four prognostic models for nonmetastatic renal cell carcinoma after nephrectomy:a multicenter European study. Cancer, 2005, 104(7):1362-1371. DOI: 10.1002/cncr.21331
|
[12] |
FICARRA V, NOVARA G, GALFANO A, et al. The stage, size, grade and necrosis' score is more accurate than the University of California Los Angeles Integrated Staging System for predicting cancer-specific survival in patients with clear cell renal cell carcinoma. BJU Int, 2009, 103(2):165-170. http://med.wanfangdata.com.cn/Paper/Detail/PeriodicalPaper_JJ027394503
|
[13] |
HADDAD H, RINI B I. Current treatment considerations in metastatic renal cell carcinoma. Curr Treat Options Oncol, 2012, 13(2):212-229. DOI: 10.1007/s11864-012-0182-8
|
[14] |
LIU Z, LV J, DING K, et al. Validation of the current prognostic models for nonmetastatic renal cell carcinoma after nephrectomy in Chinese population:a 15-year single center experience. Int J Urol, 2009, 16(3):268-273. DOI: 10.1111/j.1442-2042.2008.02229.x
|
[15] |
PARKER W P, CHEVILLE J C, FRANK I, et al. Application of the stage, size, grade, and necrosis (SSIGN) score for clear cell renal cell carcinoma in contemporary patients. Eur Urol, 2017, 71(4):665-673. DOI: 10.1016/j.eururo.2016.05.034
|
[16] |
FUJⅡ Y, SAITO K, ⅡMURA Y, et al. External validation of the Mayo Clinic cancer specific survival score in a Japanese series of clear cell renal cell carcinoma. J Urol, 2008, 180(4):1290-1295. DOI: 10.1016/j.juro.2008.06.014
|
[17] |
BEISLAND C, GUDBRANDSDOTTIR G, REISAETER L A, et al. Contemporary external validation of the Leibovich model for prediction of progression after radical surgery for clear cell renal cell carcinoma. Scand J Urol, 2015, 49(3):205-210. DOI: 10.3109/21681805.2014.980844
|
[18] |
PICHLER M, HUTTERER G C, CHROMECKI T F, et al. External validation of the Leibovich prognosis score for nonmetastatic clear cell renal cell carcinoma at a single European center applying routine pathology. J Urol, 2011, 186(5):1773-1777. DOI: 10.1016/j.juro.2011.07.034
|
[19] |
TAN M H, KANESVARAN R, LI H, et al. Comparison of the UCLA Integrated Staging System and the Leibovich score in survival prediction for patients with nonmetastatic clear cell renal cell carcinoma. Urology, 2010, 75(5):1365-1370. http://med.wanfangdata.com.cn/Paper/Detail/PeriodicalPaper_PM20022084
|
[20] |
TAN M H, LI H, CHOONG C V, et al. The Karakiewicz nomogram is the most useful clinical predictor for survival outcomes in patients with localized renal cell carcinoma. Cancer, 2011, 117(23):5314-5324. DOI: 10.1002/cncr.26193
|